A diagnosis of Netherton syndrome was made and the patient was started on antihistamines, emollients, and 10% urea. In our case, the patient presented at age 17 years. The history of his ...

If Granted Company Would have Patent Protection for QRX003 for Netherton Syndrome Until 2045 ASHBURN, Va., March (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin” ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.

ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan ...

SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for Netherton ...

Quoin’s lead product, QRX003, is currently being tested in four Netherton Syndrome clinical trials. Three of these trials are being conducted under Quoin’s open Investigational New Drug (IND ...

aimed at raising awareness about Netherton Syndrome, a poorly understood genetic disease. The first episode will air on Rare Disease Day, February 28, 2025, featuring the story of Carmon McTigue ...

Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.

ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare ...

In other recent news, Quoin Pharmaceuticals reported significant progress in its pediatric study for Netherton Syndrome, a severe skin disorder. The investigational drug, QRX003, showed promising ...

ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin” or the "Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan ...